OPTN - OptiNose: Future Outlook Beyond The Coronavirus Crisis
Introduction
The share price of OptiNose (OPTN) has not been performing well in 2020. Investors seemed to have lost confidence in the company and shares have suffered again after the company initiated an additional equity offering in mid-August. This might be short-sighted without having the predicted sell-side consensus of over $600 million (2029) in their mind. Moreover, the company expects top-line results for OPN-375 as a potential treatment for Chronic Sinusitis in H2 2021.
Chronic Sinusitis
Chronic sinusitis is an inflammation of the sinus or nasal passage and a relatively common diagnosis throughout